Who Optimizes SG&A Costs Better? Pfizer Inc. or Opthea Limited

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Pfizer Inc., a global giant, and Opthea Limited, a smaller player, offer a fascinating contrast in SG&A cost management from 2014 to 2023.

Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's robust cost management strategies, even amidst global challenges. In contrast, Opthea's SG&A expenses have seen a dramatic increase, growing by over 1,500% from 2014 to 2023. This surge indicates aggressive expansion efforts, albeit with higher operational costs.

While Pfizer's scale allows for steady expense management, Opthea's growth trajectory suggests a strategic investment in its future. The missing data for 2024 highlights the dynamic nature of financial forecasting, leaving room for speculation on future trends.